Triglide is a fibric acid derivative, which is an adjunctive therapy to diet for high cholesterol and high levels of triglyceride in the blood. First Horizon licensed the US rights for the drug from SkyePharma in May 2004.
The study in 20 healthy individuals revealed no significant effects on the pharmacokinetics of Triglide when taken alone or in combination with Pfizer’s Lipitor or Merck’s Zocor.
It has been suggested that a combination of statins and fibrates may improve the overall lipoprotein profile compared to either fibrates or LDL-lowering drugs alone. As such, there has been a movement for considering use of fibrates in combination with statins in high-risk individuals whose triglyceride levels are still elevated.
In some persons, this combination may better achieve the secondary target for non-HDL cholesterol than statins alone.
Although Triglide was generally well-tolerated, one subject experienced a possibly related serious adverse event, a seizure, approximately 12-hours post-administration.